Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.34 |
| ▸ | FEN1 | P39748 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496683 | 0.80 | ACP1 (0.35) | — | |
| SCHEMBL4488611 | 0.79 | GSK3B (0.48) | FLT4KDRFLT3 | |
| SCHEMBL1234014 | 0.79 | GSK3B (0.52) | — | |
| SCHEMBL1378240 | 0.78 | ALOX5AP (0.38) | SCN9ANPC1SCN5AALOX5APFEN1 | |
| SCHEMBL6486540 | 0.78 | KMO (0.36) | SCN9ANPC1SCN5ADGAT1 | |
| SCHEMBL13713049 | 0.78 | SCN9A (0.40) | SCN9ASCN5ACSNK2A1MEN1KMT2A | |
| SCHEMBL4109728 | 0.77 | NPC1 (0.45) | SCN9ANPC1SCN5AALOX5APFEN1 | |
| SCHEMBL27604149 | 0.77 | KDM4E (0.32) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL2662090 | 0.76 | NPC1 (0.34) | SCN9ANPC1ALOX5APFEN1DGAT1 | |
| SCHEMBL3515098 | 0.74 | MAPT (0.42) | NPC1ALOX5APFEN1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011026340-A | INTERMEDIATE COMPOUND FOR SYNTHESIZING AMINO INDAZOLE DERIVATIVE USEFUL AS KINASE INHIBITOR | AVENTIS PHARMA SA | 2011-02-10 | — | — | JP | disclosed |
| US-7582669-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7166629-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | AVENTIS PHARMA S.A. (FR) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SUCNR1, CNR1, SIGMAR1 | SCN9A 958/4885NPC1 1006/4885SCN5A 1483/4885 |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | OXSR1, OXER1, OXGR1 | SCN9A 1552/4885NPC1 1201/4885SCN5A 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.